Everyday errors parent's make could be damaging kid's skin – quiz reveals if you're to blame for nasty reactions
The test comes after research found parents may be unwittingly damaging their child's skin by making everyday errors such as allowing them to spend too long in the sun or using fragranced products.
1
The study of 700 parents with children aged up to four, found 21 per cent are doing something considered potentially damaging to their child's skin every few days, or daily.
But more than one third (35 per cent) didn't realise the actions they were taking were potentially harmful.
Pharmacist and health and wellness educator Nyrah Saleem, working with WaterWipes, which commissioned the research, said: 'Becoming a new parent is overwhelming but small tweaks can help improve your child's skin health.
'Nappy rash is an issue for two-fifths of parents.
"Each added ingredient in skin products increases the chance of a skin reaction, so check labels and use products with minimal ingredients to reduce the risk.'
The study also revealed 73 per cent of parents have sought medical treatment for their kids due to skin irritation - and upon doing so, 24 per cent found too much sun exposure was the cause.
For 23 per cent, the use of harsh washing detergents was the reason, while 22 per cent simply needed to change nappies more.
While 18 per cent found skin reactions were due to using creams, moisturisers or other skin care that had been designed for adults and not younger skin and for 15 per cent, irritations were caused by products with a long list of ingredients.
Around one in 10 (12 per cent) parents polled confessed they rarely or never check the ingredients in products they buy for children.
More than a quarter (27 per cent) admitted to not being particularly aware of the number of ingredients in them.
Distressing footage shows tot whose full-body eczema is so extreme he writhes around on the floor
While 21 per cent didn't even know there was a link between skincare products and their child's skin reactions.
More than half (55 per cent) usually stick with the same brands when it comes to what they use on their kids, according to the OnePoll.com figures.
But selecting skincare or similar products with minimal ingredients is only a priority for 20 per cent.
Dr Emer Gilligan from WaterWipes, which uses just 99.9 per cent water and a drop of fruit extract, said: 'As parents, we all want the very best for our children, and that starts with the products we use on their skin.
'A baby's skin is thinner and more delicate than an adult's and any additive has the potential to cause irritation.
'Choosing skincare formulations with fewer ingredients can help to minimise the risk of a skin reaction, so be sure to check labels and choose products with minimal ingredients.'
Less is more
Choose products with as few ingredients as possible. The simpler the formula, the less chance of irritation.
Avoid fragrances
Fragranced products may smell nice but are one of the top causes of allergic skin reactions in babies.
Ditch harsh wipes
Some wipes contain alcohol or essential oils, which can strip moisture from delicate skin.
Check labels carefully
Even 'natural' products can have irritating additives — always read the back, not just the front.
Watch for redness or dryness
These are early signs of skin barrier damage. Swap out products immediately and opt for fragrance-free, pH-balanced options.
Keep it clean but not overdone
Over-bathing can dry out baby skin. Stick to short baths with lukewarm water and avoid bubble baths.
Moisturise within five minutes of bathing
Lock in hydration by applying a gentle, fragrance-free emollient on damp skin.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
21 minutes ago
- The Sun
Fears for Princess stuck in three-year coma as she faces grim health battle after developing ‘severe' infection
FEARS have been raised for a Thai princess after the royal palace shared concerning health updates following her three-year-long coma battle. Princess Bajrakitiyabha Mahidol, the eldest daughter of King Vajiralongkorn, is said to have developed a severe infection. 5 5 5 The 46-year-old, affectionately known as Princess Bha, collapsed in December, 2022, while training her dogs in Nakhon Ratchasima, northeast of Bangkok. She has been in a coma ever since. The Bureau of the Royal Household gave the first update on her condition in more than two years on Friday, saying she had suffered a "severe" blood infection. The palace said in a following update that a team of doctors were closely monitoring her situation. It read: "The medical team said that she remains in a state of low blood pressure, requiring continuous treatment. "Doctors are administering medication to stabilise her blood pressure, along with medical equipment and antibiotics to support kidney function and breathing." Over the years, some reports have suggested her health condition is far more serious than the palace is letting on. Princess Bajrakitiyabha was training her dogs at a working dog championship organised by the Thaiarmy when she collapsed. Paramedics rushed her to a nearby hospital before a helicopter took her to Bangkok's Chulalongkorn health facility. Bajrakitiyabha is the daughter of the king's first wife, Princess Soamsawali. She has been part of her father's inner circle since he came to the throne in 2016 and is a senior officer in the king's personal guard. The fitness enthusiast is widely viewed as the most suitable successor for her father, who turned 70 this year. She has post-graduate law degrees from two US universities and has long called for prison reforms in Thailand. She was also the Thai ambassador to Austria between 2012 and 2014. The 73-year-old king, who has seven children from four marriages, has not announced his chosen heir. Though succession rules in Thailand favour men. 5 5
The Independent
an hour ago
- The Independent
New advanced bladder cancer treatment can ‘double chances of survival'
A new treatment for advanced bladder cancer which doubles survival time has been approved for NHS use. The treatment for advanced bladder cancer had not significantly changed since the 1980s. Now, experts say the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease. They said there had been real 'unmet need' for patients with advanced disease, with some 29 per cent of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30 per cent) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5 per cent of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.
The Independent
an hour ago
- The Independent
RFK Jr. says he finds it ‘convenient' to wear jeans to the gym
Robert F. Kennedy Jr. explained on Fox News that he works out in jeans for convenience, as he would go hiking before the gym and found it practical. Kennedy recently participated in the 'Pete and Bobby Challenge' with Defense Secretary Pete Hegseth, completing 50 pull-ups and 100 push-ups in under six minutes while wearing jeans. The challenge aims to encourage American youth to be fit, aligning with Kennedy's 'Make America Healthy Again' (MAHA) agenda, which promotes public health, reducing artificial food additives, and re-evaluating health choices for children. Kennedy's MAHA movement, which echoes President Donald Trump 's 'Make America Great Again' slogan, focuses on health issues, including a reassessment of childhood vaccines. While experts agree with Kennedy's claim about increasing chronic conditions in American children, critics like John Oliver and health experts have raised concerns about the 'dangerous' nature of some of MAHA's proposed solutions, particularly the defunding of mRNA vaccine research.
